Generic drug
Enoxaparin price, strengths & recalls
Generic of Lovenox
Pharmacies pay $29.89 for 4 mL of Enoxaparin 100 mg/mL, 0.4 mL prefilled syringe this week, and from $25.61 to $90.76 across its 8 priced strengths and forms. 13 manufacturers make it. It is in shortage (being discontinued). 3 recalls are ongoing. Its official label last changed on September 21, 2026.
Being discontinued3 open recallsGeneric- Fair cash price
- $44.87
- Strengths
- 8
- Makers
- 13
- Updated
- Nov 11
Enoxaparin price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 100 mg/mL injection | $9.98 | $29.93 / 3 mL |
| 100 mg/mL, 0.3 mL prefilled syringe | $8.54 | $25.61 / 3 mL |
| 100 mg/mL, 0.4 mL prefilled syringe | $7.47 | $29.89 / 4 mL |
| 100 mg/mL, 0.6 mL prefilled syringe | $7.31 | $43.85 / 6 mL |
| 100 mg/mL, 0.8 mL prefilled syringe | $7.00 | $55.99 / 8 mL |
| 100 mg/mL, 1 mL prefilled syringe | $6.78 | $67.83 / 10 mL |
| 150 mg/mL, 0.8 mL prefilled syringe | $10.57 | $84.56 / 8 mL |
| 150 mg/mL, 1 mL prefilled syringe | $9.08 | $90.76 / 10 mL |
Brand names of enoxaparin
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Lovenox, Injection, 40 mg/.4 mL (NDC 0075-0620-40)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 30 mg/.3 mL (NDC 0075-8013-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 60 mg/.6 mL (NDC 0075-8016-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Lovenox, Injection, 60 mg/.6 mL (NDC 0075-0621-60)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
- Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01)Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available...
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 7 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Enoxaparin
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ENOXAPARIN SODIUM injection safely and effectively. See full prescribing information for ENOXAPARIN SODIUM injection.ENOXAPARIN SODIUM injection, for subcutaneous and intravenous useInitial U.S. Approval: 1993
WARNING: SPINAL/EPIDURAL HEMATOMAS
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery
Optimal timing between the administration of enoxaparin sodium and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7)].
WARNING: SPINAL/EPIDURAL HEMATOMAS
See full prescribing information for complete boxed warning.
Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
Use of indwelling epidural catheters
Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants
A history of traumatic or repeated epidural or spinal punctures
A history of spinal deformity or spinal surgery
Optimal timing between the administration of enoxaparin sodium and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. (5.1, 7)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA020164 · Sanofi Aventis US
- First approved
- March 29, 1993 (33 years ago)
- Latest approved change
- July 28, 2023
- Approved label
- PDF, Jul 31, 2023
- Generic makers
- 9 approved generic applications on the market
Enoxaparin questions
How much does enoxaparin cost without insurance?
Pharmacies pay about $29.89 for 4 mL of enoxaparin 100 mg/mL, 0.4 mL prefilled syringe ($7.47 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $44.87. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of enoxaparin?
Enoxaparin is sold as Lovenox. The generic has the same active ingredient and usually costs far less.
Is enoxaparin in shortage?
Yes. 24 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has enoxaparin been recalled?
7 recalls on record, 3 ongoing. Recalls name specific lots - check yours.
When did the enoxaparin label last change?
The official label was last updated on September 21, 2026 (version 23). See what changed.
Talk about enoxaparin
No comments yet. Questions, tips, what worked for you - start the conversation.